



Update regarding Hemlibra® (emicizumab injection): Drug Product Shelf Life Reduction

February 16, 2021

Dear Transfusion Service Medical Director / Technical Lead,

We are writing to notify you of a recent update to the Hemlibra® (emicizumab injection).

Effective January 21, 2021, Health Canada has granted a Notifiable Change (NC) for the drug product shelf life for HEMLIBRA. The updated shelf life for HEMLIBRA has been reduced from 30 to 24 months.

This recent update for HEMLIBRA does not change the current prescribing method of the medicine. Patients are advised to consult their physician for further information regarding this recent update. This change only affects newly manufactured vials, and all previously manufactured vials may be used until the expiry date as printed on the vial label. Patients are advised to check the expiry date on the box and vial label and are advised to not use HEMLIBRA if the expiry date has passed.

The risk/benefit profile of HEMLIBRA remains unchanged. Our priority remains to deliver the highest quality medicines and the transfer filter needle provides additional confidence for patients and Healthcare professionals in the use of HEMLIBRA.

Should you have any additional questions, please contact a member of the Roche Canada Medical Information team:

Email: mississauga.canada_medinfo@roche.com

Tel.: 1-888-762-4388

Fax.: 1-905-542-5610

Sincerely,

Paul Bloomfield
Manager, Quality Management
Hoffmann-La Roche Limited
7070 Mississauga Road
Mississauga, ON L5N 5M8 Canada